John M. Louis
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
John M. Louis has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Alan R. Kimmel
From the ‡Laboratory of Chemical Physics, NIDDK, National Institutes of Health, Bethesda, Maryland 20892-0580, the ¶Laboratory of Cellular and Developmental Biology, NIDDK, National Institutes of Health, Bethesda, Maryland 20892-2715, the ‖Laboratory of Protein Expression, NIAMS, National Institutes of Health, Bethesda, Maryland 20892-2775, and the **Laboratory of Bioorganic Chemistry, NIDDK, National Institutes of Health, Bethesda, Maryland 20892-0820
3 shared publications- Angela M. Gronenborn
Department of Chemistry and Biochemistry, University of Delaware, Newark, Delaware, USA
2 shared publications Ewald M. Wondrak
From the ‡Laboratory of Chemical Physics, NIDDK, National Institutes of Health, Bethesda, Maryland 20892-0580, the ¶Laboratory of Cellular and Developmental Biology, NIDDK, National Institutes of Health, Bethesda, Maryland 20892-2715, the ‖Laboratory of Protein Expression, NIAMS, National Institutes of Health, Bethesda, Maryland 20892-2775, and the **Laboratory of Bioorganic Chemistry, NIDDK, National Institutes of Health, Bethesda, Maryland 20892-0820
2 shared publicationsNashaat T. Nashed
From the ‡Laboratory of Chemical Physics, NIDDK, National Institutes of Health, Bethesda, Maryland 20892-0580, the ¶Laboratory of Cellular and Developmental Biology, NIDDK, National Institutes of Health, Bethesda, Maryland 20892-2715, the ‖Laboratory of Protein Expression, NIAMS, National Institutes of Health, Bethesda, Maryland 20892-2775, and the **Laboratory of Bioorganic Chemistry, NIDDK, National Institutes of Health, Bethesda, Maryland 20892-0820
2 shared publicationsDavid R. Davies
Laboratories of Chemical Physics, Molecular Biology, Bioorganic Chemistry, and Cellular and Developmental Biology, National Institute of Diabetes, Digestive and Kidney Diseases, The National Institutes of Health, Bethesda, Maryland 20892
1 shared publicationDennis A. Torchia
From the Laboratories of ‡Chemical Physics and ‡Bioorganic Chemistry, NIDDK and the ‖Molecular Structural Biology Unit, NIDCR, National Institutes of Health, Bethesda, Maryland 20892
1 shared publication
Latest Publications
- Open Access
- 1 February 2003
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 278 (8) , 6085-6092
Revisiting Monomeric HIV-1 Protease
- 1 February 2003
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 278 (8) , 6085-6092
Open AccessRevisiting Monomeric HIV-1 Protease
- 1 September 1999
- Published by Springer Nature in Nature Structural & Molecular Biology
- Vol. 6 (9) , 868-875
Autoprocessing of HIV-1 protease is tightly coupled to protein folding.
In the Gag-Pol polyprotein of HIV-1, the 99-amino acid protease is flanked at its N-terminus by a transframe region (TFR) composed of the transframe octapeptide (TFP) and 48 amino acids of the p6pol, separated by a protease cleavage site. The intact precursor (TFP-p6pol-PR) has very low dimer stability relative to that of the mature enzyme and exhibits negligible levels of stable tertiary structure. Thus, the TFR functions by destabilizing the native structure, unlike proregions found in zymogen forms of monomeric aspartic proteases. Cleavage at the p6pol-PR site to release a free N-terminus of protease is concomitant with the appearance of enzymatic activity and formation of a stable tertiary structure that is characteristic of the mature protease as demonstrated by nuclear magnetic resonance. The release of the mature protease from the precursor can either occur in two steps at pH values of 4 to 6 or in a single step above pH 6. The mature protease forms a dimer through a four-stranded beta-sheet at the interface. Residues 1-4 of the mature protease from each subunit constitute the outer strands of the beta-sheet, and are essential for maintaining the stability of the free protease but are not a prerequisite for the formation of tertiary structure and catalytic activity. Our experimental results provide the basis for the model proposed here for the regulation of the HIV-1 protease in the viral replication cycle.
- 1 September 1999
- Published by Springer Nature in Nature Structural & Molecular Biology
- Vol. 6 (9) , 868-875
Autoprocessing of HIV-1 protease is tightly coupled to protein folding.
In the Gag-Pol polyprotein of HIV-1, the 99-amino acid protease is flanked at its N-terminus by a transframe region (TFR) composed of the transframe octapeptide (TFP) and 48 amino acids of the p6pol, separated by a protease cleavage site. The intact precursor (TFP-p6pol-PR) has very low dimer stability relative to that of the mature enzyme and exhibits negligible levels of stable tertiary structure. Thus, the TFR functions by destabilizing the native structure, unlike proregions found in zymogen forms of monomeric aspartic proteases. Cleavage at the p6pol-PR site to release a free N-terminus of protease is concomitant with the appearance of enzymatic activity and formation of a stable tertiary structure that is characteristic of the mature protease as demonstrated by nuclear magnetic resonance. The release of the mature protease from the precursor can either occur in two steps at pH values of 4 to 6 or in a single step above pH 6. The mature protease forms a dimer through a four-stranded beta-sheet at the interface. Residues 1-4 of the mature protease from each subunit constitute the outer strands of the beta-sheet, and are essential for maintaining the stability of the free protease but are not a prerequisite for the formation of tertiary structure and catalytic activity. Our experimental results provide the basis for the model proposed here for the regulation of the HIV-1 protease in the viral replication cycle.
- Open Access
- 1 August 1999
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 274 (33) , 23437-23442
Proteolytic Processing of HIV-1 Protease Precursor, Kinetics and Mechanism
- 1 August 1999
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 274 (33) , 23437-23442
Open AccessProteolytic Processing of HIV-1 Protease Precursor, Kinetics and Mechanism
- Open Access
- 1 March 1999
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 274 (10) , 6660-6666
Stabilization from Autoproteolysis and Kinetic Characterization of the Human T-cell Leukemia Virus Type 1 Proteinase
- 1 March 1999
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 274 (10) , 6660-6666
Open AccessStabilization from Autoproteolysis and Kinetic Characterization of the Human T-cell Leukemia Virus Type 1 Proteinase
- 1 February 1998
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 37 (8) , 2105-2110
Hydrophilic Peptides Derived from the Transframe Region of Gag-Pol Inhibit the HIV-1 Protease
The HIV-1 transframe region (TFR) is between the structural and functional domains of the Gag-Pol polyprotein, flanked by the nucleocapsid and the protease domains at its N and C termini, respectively. Transframe octapeptide (TFP) Phe-Leu-Arg-Glu-Asp-Leu-Ala-Phe, the N terminus of TFR, and its analogues are competitive inhibitors of the action of the mature HIV-1 protease. The smallest, most potent analogues are tripeptides: Glu-Asp-Leu and Glu-Asp-Phe with Ki values of ∼50 and ∼20 μM, respectively. Substitution of the acidic amino acids in the TFP by neutral amino acids and d or retro-d configurations of Glu-Asp-Leu results in an >40-fold increase in Ki. Protease inhibition by Glu-Asp-Leu is dependent on a protonated form of a group with a pKa of 3.8; unlike other inhibitors of HIV-1 protease which are highly hydrophobic, Glu-Asp-Leu is extremely soluble in water, and its binding affinity decreases with increasing NaCl concentration. However, Glu-Asp-Leu is a poor inhibitor (Ki ∼ 7.5 mM) of the mammalian aspartic acid protease pepsin. X-ray crystallographic studies at pH 4.2 show that the interactions of Glu at P2 and Leu at P1 of Glu-Asp-Leu with residues of the active site of HIV-1 protease are similar to those of other product−enzyme complexes. It was not feasible to understand the interaction of intact TFP with HIV-1 protease under conditions of crystal growth due to its hydrolysis giving rise to two products. The sequence-specific, selective inhibition of the HIV-1 protease by the viral TFP suggests a role for TFP in regulating protease function during HIV-1 replication.
- 1 February 1998
- Published by American Chemical Society (ACS) in Biochemistry
- Vol. 37 (8) , 2105-2110
Hydrophilic Peptides Derived from the Transframe Region of Gag-Pol Inhibit the HIV-1 Protease
The HIV-1 transframe region (TFR) is between the structural and functional domains of the Gag-Pol polyprotein, flanked by the nucleocapsid and the protease domains at its N and C termini, respectively. Transframe octapeptide (TFP) Phe-Leu-Arg-Glu-Asp-Leu-Ala-Phe, the N terminus of TFR, and its analogues are competitive inhibitors of the action of the mature HIV-1 protease. The smallest, most potent analogues are tripeptides: Glu-Asp-Leu and Glu-Asp-Phe with Ki values of ∼50 and ∼20 μM, respectively. Substitution of the acidic amino acids in the TFP by neutral amino acids and d or retro-d configurations of Glu-Asp-Leu results in an >40-fold increase in Ki. Protease inhibition by Glu-Asp-Leu is dependent on a protonated form of a group with a pKa of 3.8; unlike other inhibitors of HIV-1 protease which are highly hydrophobic, Glu-Asp-Leu is extremely soluble in water, and its binding affinity decreases with increasing NaCl concentration. However, Glu-Asp-Leu is a poor inhibitor (Ki ∼ 7.5 mM) of the mammalian aspartic acid protease pepsin. X-ray crystallographic studies at pH 4.2 show that the interactions of Glu at P2 and Leu at P1 of Glu-Asp-Leu with residues of the active site of HIV-1 protease are similar to those of other product−enzyme complexes. It was not feasible to understand the interaction of intact TFP with HIV-1 protease under conditions of crystal growth due to its hydrolysis giving rise to two products. The sequence-specific, selective inhibition of the HIV-1 protease by the viral TFP suggests a role for TFP in regulating protease function during HIV-1 replication.
- Open Access
- 1 October 1997
- Published by Wiley in European Journal of Biochemistry
- Vol. 249 (2) , 523-530
Crystallographic Analysis of Human Immunodeficiency Virus 1 Protease with an Analog of the Conserved CA‐p2 Substrate
Human immunodeficiency virus type 1 (HIV‐1) protease hydrolysis of the Gag CA‐p2 cleavage site is crucial for virion maturation and is optimal at acidic pH. To understand the processing of the CA‐p2 site, we have determined the structure of HIV‐1 protease complexed with an analog of the CA‐p2 site, the reduced peptide inhibitor Arg‐Val‐Leu‐r‐Phe‐Glu‐Ala‐Ahx‐NH2 [r denotes the reduced peptide bond and Ahx 2‐aminohexanoic acid (norleucine), respectively]. The crystal structure was refined to an R‐factor of 0.17 at 0.21‐nm resolution. The crystals have nearly the same lattice as related complexes in P212121, which have twofold disordered inhibitor, but are in space group P21, and the asymmetric unit contains two dimers of HIV‐1 protease related by 1800 rotation. An approximate non‐crystallographic symmetry has replaced the exact crystal symmetry resulting in well‐ordered inhibitor structure. Each protease dimer binds one ordered inhibitor molecule, but in opposite orientations. The interactions of the inhibitor with the two dimers are very similar for the central P2 Val to P2' Glu residues, but show more variation for the distal P3 Arg and P4' Ahx residues. Importantly, the carboxylate oxygens of Glu at P2' in the inhibitor are within hydrogen‐bonding distance of a carboxylate oxygen of Asp30 of the protease suggesting that the two side chains share a proton. This interaction suggests that the enzyme‐substrate complex is additionally stabilized at lower pH. The importance of this interaction is emphasized by the absence of polymorphisms of Asp30 in the protease and variants of P2' Glu in the critical CA‐p2 cleavage site.
- 1 October 1997
- Published by Wiley in European Journal of Biochemistry
- Vol. 249 (2) , 523-530
Open AccessCrystallographic Analysis of Human Immunodeficiency Virus 1 Protease with an Analog of the Conserved CA‐p2 Substrate
Human immunodeficiency virus type 1 (HIV‐1) protease hydrolysis of the Gag CA‐p2 cleavage site is crucial for virion maturation and is optimal at acidic pH. To understand the processing of the CA‐p2 site, we have determined the structure of HIV‐1 protease complexed with an analog of the CA‐p2 site, the reduced peptide inhibitor Arg‐Val‐Leu‐r‐Phe‐Glu‐Ala‐Ahx‐NH2 [r denotes the reduced peptide bond and Ahx 2‐aminohexanoic acid (norleucine), respectively]. The crystal structure was refined to an R‐factor of 0.17 at 0.21‐nm resolution. The crystals have nearly the same lattice as related complexes in P212121, which have twofold disordered inhibitor, but are in space group P21, and the asymmetric unit contains two dimers of HIV‐1 protease related by 1800 rotation. An approximate non‐crystallographic symmetry has replaced the exact crystal symmetry resulting in well‐ordered inhibitor structure. Each protease dimer binds one ordered inhibitor molecule, but in opposite orientations. The interactions of the inhibitor with the two dimers are very similar for the central P2 Val to P2' Glu residues, but show more variation for the distal P3 Arg and P4' Ahx residues. Importantly, the carboxylate oxygens of Glu at P2' in the inhibitor are within hydrogen‐bonding distance of a carboxylate oxygen of Asp30 of the protease suggesting that the two side chains share a proton. This interaction suggests that the enzyme‐substrate complex is additionally stabilized at lower pH. The importance of this interaction is emphasized by the absence of polymorphisms of Asp30 in the protease and variants of P2' Glu in the critical CA‐p2 cleavage site.